

各種癌での癌免疫療法の実際 参考文献

胃癌

1. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. *Clin Cancer Res.* 2001 Aug;7(8):2277-84.
2. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. *Clin Cancer Res.* 2002 Nov;8(11):3394-400.
3. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. *Clin Cancer Res.* 2002 Jun;8(6):1767-71.

大腸癌

1. Hoover, H. C., Jr., Surdyke, M. G., Dangel, R. B., Peters, L. C., and Hanna, M. G., Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. *Cancer*, *55*:1236-1243, 1985.
2. Gray, B. N., Walker, C., Andrewartha, L., Freeman, S., and Bennett, R. C. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. *J Surg Oncol*, *40*:34-37, 1989.
3. Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, W., and Schirrmacher, V. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. *Cancer Immunol Immunother*, *35*:325-330, 1992.
4. Hoover, H. C., Jr., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madariaga, J., Muenz, L. R., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. *J Clin Oncol*, *11*:390-399, 1993.
5. Vermorcken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., Hanna, M. G., Jr., and Pinedo, H. M. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. *Lancet*, *353*:345-350, 1999.
6. Harris, J. E., Ryan, L., Hoover, H. C., Jr., Stuart, R. K., Oken, M. M., Benson, A. B., 3rd, Mansour, E., Haller, D. G., Manola, J., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. *J Clin Oncol*, *18*:148-157, 2000.

7. Rains, N., Cannan, R. J., Chen, W., and Stubbs, R. S. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. *Hepatology*, *48*: 347-351, 2001.
8. Morse, M. A., Nair, S. K., Mosca, P. J., Hobeika, A. C., Clay, T. M., Deng, Y., Boczkowski, D., Proia, A., Neidzwiecki, D., Clavien, P. A., Hurwitz, H. I., Schlom, J., Gilboa, E., and Lyerly, H. K. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. *Cancer Invest*, *21*: 341-349, 2003.
9. Liu, K. J., Wang, C. C., Chen, L. T., Cheng, A. L., Lin, D. T., Wu, Y. C., Yu, W. L., Hung, Y. M., Yang, H. Y., Juang, S. H., and Whang-Peng, J. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. *Clin Cancer Res*, *10*: 2645-2651, 2004.
10. Sato, Y., Maeda, Y., Shomura, H., Sasatomi, T., Takahashi, M., Une, Y., Kondo, M., Shinohara, T., Hida, N., Katagiri, K., Sato, K., Sato, M., Yamada, A., Yamana, H., Harada, M., Itoh, K., and Todo, S. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. *Br J Cancer*, *90*: 1334-1342, 2004.
11. Dillman, R. O., Soori, G., DePriest, C., Nayak, S. K., Beutel, L. D., Schiltz, P. M., de Leon, C., and O'Connor, A. A. Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group. *Cancer Biother Radiopharm*, *18*: 727-733, 2003.
12. Cunningham, Y., Humblet, S., Siena, D., Khayat, H., Bleiberg, A., Santoro, D., Bets, M., Mueser, A., Harstrick, E., Van Cutsem. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). *Proc Am Soc Clin Oncol* *22*: page 252, 2003 (abstr 1012)

肺癌

1. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. *Cancer*. 1997 Jul 1;80(1):42-9.
2. Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa K, Fujino S. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. *Int J Mol Med*. 2003 Oct;12(4):493-502.
3. Nemunaitis J. GVAX (GM-CSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. *J Control Release*. 2003 Aug 28;91(1-2):225-31.

乳癌

1. Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa K, Fujino S. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. *Int J Mol Med.* 2003 Oct;12(4):493-502.
2. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarreal M, Kufe D. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. *Clin Cancer Res.* 2004 Jul 15;10(14):4699-708.
3. Miles D, Papazisis K. Rationale for the Clinical Development of STn-KLH (Theratope(R)) and Anti-MUC-1 Vaccines in Breast Cancer. *Clin Breast Cancer.* 2003 Feb;3 Suppl 4:S134-8.

原発性肝臓癌（肝細胞癌）

1. Ichida, T., Higuchi, K., Arakawa, K., Ohta, H., Sugiyama, K., Miyagiwa, M., Nohzawa, A., Satoh, T., Sasaki, H., and Ichida, F. Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2. *Cancer Chemother Pharmacol*, 23 Suppl: S45-48, 1989.
2. Onishi, S., Saibara, T., Fujikawa, M., Sakaeda, H., Matsuura, Y., Matsunaga, Y., and Yamamoto, Y. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. *Hepatology*, 10: 349-353, 1989.
3. Yeung, A. W., Pang, Y. K., Tsang, Y. C., Wong, S. W., and Leung, J. S. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial. *Cancer*, 71: 3633-3639, 1993.
4. Haruta, I., Yamauchi, K., Aruga, A., Komatsu, T., Takasaki, K., Hayashi, N., and Hanyu, F. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. *J Immunother Emphasis Tumor Immunol*, 19: 218-223, 1996.
5. Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., and Kakizoe, T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. *Lancet*, 356: 802-807, 2000.
6. Iwashita, Y., Tahara, K., Goto, S., Sasaki, A., Kai, S., Seike, M., Chen, C. L., Kawano, K., and Kitano, S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. *Cancer Immunol Immunother*, 52: 155-161, 2003.8.
7. Peng, B. G., Liu, S. Q., Kuang, M., He, Q., Totsuka, S., Huang, L., Huang, J., Lu, M. D., Liang, L. J., Leong, K. W., and Ohno, T. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. *Jpn J Cancer Res*, 93: 363-368, 2002.

8. Ladhams, A., Schmidt, C., Sing, G., Butterworth, L., Fielding, G., Tesar, P., Strong, R., Leggett, B., Powell, L., Maddern, G., Ellem, K., and Cooksley, G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. *J Gastroenterol Hepatol*, *17*: 889-896, 2002.
9. Kuang, M., Peng, B. G., Lu, M. D., Liang, L. J., Huang, J. F., He, Q., Hua, Y. P., Totsuka, S., Liu, S. Q., Leong, K. W., and Ohno, T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. *Clin Cancer Res*, *10*: 1574-1579, 2004.

膵臓癌

1. 有賀 淳、谷川啓司、清水公一、羽鳥 隆、須藤俊美、高崎 健。MUC1 ペプチドを用いたがんワクチン。 *血液・腫瘍科*, *45*(1), 28-35, 2002
2. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. *J Surg Res*. 1996 Jun; *63*(1): 298-304.
3. Thomas Am, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. *J Exp Med*. 2004 Aug 2;*200*(3):297-306.

腎臓癌

1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. *N Engl J Med* 1987, *316*:889-95.
2. Pizza G, Vinci CD, Conte GL, Maver P, Dragoni E, Aiello E, Fornarola V, Bergami T, Busutti L, Boriani S, Palareti A, Capanna R. immunotherapy of metastatic kidney cancer.
3. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and Interleukin-2. *1997 Feb 2*;*15*:796-807.
4. Zou X, Jun do Y, Thomas AM, Huang X, Huang LQ, Mautner J. Mo W, Robbins PF, Pardoll DM, Jaffee EM. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. *Cancer Res*. 2005 Feb *1*;*65*(3):1079-88.
5. Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. *Clin Cancer Res*. 2003 Sep *1*;*9*(10 Pt 1):3562-70.

6. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. *J Clin Oncol.* 2003 Mar 1;21(5):884-90.

前立腺癌

1. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. *Prostate.* 2004 Aug 1;60(3):197-204.
2. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. *Prostate.* 1999 Jan 1;38(1):73-8.